Moderna Reaches Major Patent Settlement on mRNA Vaccines
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moderna ( (MRNA) ) has issued an announcement.
On March 3, 2026, Moderna entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences to resolve all worldwide patent litigation related to Spikevax, mRESVIA and its broader infectious disease portfolio. The deal grants Moderna a fully paid-up, royalty-free, irrevocable worldwide license for SM-102-based LNP infectious disease vaccines and a covenant not to sue, eliminating future royalty obligations on key products.
Under the agreement, Moderna will make a $950 million noncontingent lump-sum payment to Arbutus/Genevant by July 8, 2026, and both sides will move to dismiss or withdraw outstanding claims with prejudice. A further contingent payment of up to $1.3 billion hinges on the outcome of Moderna’s appeal to the Federal Circuit over the applicability of 28 U.S.C. § 1498 to doses sold to the U.S. government, with mechanisms for prorated payment, potential repayment with interest, and binding arbitration if needed.
The settlement removes significant legal uncertainty around Moderna’s current and future infectious disease vaccines and clarifies its financial exposure tied to past government-supplied doses. By securing long-term freedom to operate on SM-102-based LNP formulations, Moderna strengthens its strategic positioning in the competitive mRNA vaccines market and provides greater visibility to stakeholders on litigation risk and cash commitments.
The most recent analyst rating on (MRNA) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Moderna stock, see the MRNA Stock Forecast page.
Spark’s Take on MRNA Stock
According to Spark, TipRanks’ AI Analyst, MRNA is a Neutral.
The score is held down mainly by weak financial performance (steep revenue contraction, large losses, and material cash burn), partially offset by low leverage and liquidity. Earnings-call commentary supports a mid-range outlook due to cost discipline and 2026 growth guidance, but FDA/regulatory uncertainty and H2 revenue concentration remain meaningful risks. Technically, longer-term trend support is constructive, though near-term price softness persists; valuation remains constrained by negative earnings and no dividend.
To see Spark’s full report on MRNA stock, click here.
More about Moderna
Moderna, Inc. is a biotechnology company focused on developing and commercializing messenger RNA-based vaccines and therapeutics, particularly in infectious diseases. Its marketed products include the COVID-19 vaccine Spikevax and mRESVIA, and its pipeline features candidates such as mNEXSPIKE and mCOMBRIAX, targeting a broad global vaccines market.
Average Trading Volume: 11,937,087
Technical Sentiment Signal: Buy
Current Market Cap: $19.68B
See more data about MRNA stock on TipRanks’ Stock Analysis page.
